Drug-Drug Interaction Study of Multiple Doses of Pacritinib and CYP450 And, Transporter Substrates, and CYP450 3A4 Inducers and Inhibitors
Abstract
This is a Phase 1, open-label, fixed-sequence, 2-part DDI study. Subjects will participate in only 1 study part.
Conditions: Drug Interactions.
Primary outcome: Change in area under curve (AUC) of individual substrates between cocktail alone and cocktail combined with pacritinib administration; Change in maximum plasma concentration (Cmax) of individual substrates between cocktail alone and cocktail combined with pacritinib administration; Change in area under curve (AUC) of pacritinib alone and pacritinib + bosentan administration; Change in Cmax of pacritinib alone and pacritinib + bosentan administration; Change in AUC of pacritinib alone and pacritinib + fluconazole administration; Change in Cmax of pacritinib alone and pacritinib + fluconazole administration.
Enrollment: 60 participants.
How strong is the evidence?
Evidence Hub reads this as a clinical trial, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 60 participants or records.
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.